FOR IMMEDIATE RELEASE

Artemis Therapeutics Announces Advisory Board of Leading Experts in AI, Drug Discovery, Clinical Oncology, Biotechnology and Capital Markets

Distinguished advisory board brings together internationally recognized leaders to support the advancement of the Company's Artemis.AI™ drug discovery platform and therapeutic development programs

VANCOUVER, BC — October 27, 2026 — Artemis Therapeutics Inc. ("Artemis" or the "Company"), a biopharma company developing advanced artificial intelligence technologies to accelerate the identification and development of novel therapeutics, today announced the formation of its Advisory Board. The Artemis Advisory Board brings together internationally recognized leaders in artificial intelligence, drug discovery and development, oncology, biotechnology and capital markets.

The newly established Advisory Board will provide strategic, scientific and financial guidance as the Company advances its proprietary *Artemis.AI*™ platform and builds a portfolio of drug discovery and development programs. The Advisory Board's collective expertise will support Artemis as it advances its AI-enabled drug discovery and development platform, translates its computational discoveries into promising drug candidates, and identifies opportunities for scientific and commercial collaboration.

Frank Holler, Executive Chairman and CEO of Artemis Therapeutics, commented:

"Establishing an Advisory Board of this calibre represents an important milestone for Artemis. We have assembled an exceptional group of individuals whose expertise spans the drug discovery and development continuum, from computational science and molecular biology to drug development, clinical oncology and strategic investment. The Board's collective expertise and experience will be invaluable as we advance our

technology platform, develop our therapeutic pipeline and pursue business development opportunities."

Advisory Board Appointments

Dr. Alexander (Alex) Tropsha

Dr. Tropsha is the K.H. Lee Distinguished Professor and Director of the Laboratory for Molecular Modeling at the University of North Carolina Eshelman School of Pharmacy and Chief Domain Scientist for Molecular Informatics at the Renaissance Computing Institute (RENCI). An internationally recognized leader in cheminformatics, quantitative structure-activity relationship (QSAR) modeling and computational drug discovery, he has spent more than three decades advancing the rigorous application of chemical information and predictive modeling to molecular science.

Dr. Tropsha's research has helped establish foundational standards for computational model development and validation, and he has trained more than 80 graduate and postdoctoral researchers. Dr. Tropsha was recently named the recipient of the American Chemical Society's prestigious 2027 Herman Skolnik Award in recognition of his outstanding contributions to chemical information science.

Dr. Poul Sorensen

Dr. Sorensen is a Distinguished Scientist at the BC Cancer Agency, a Professor in the Department of Pathology and Laboratory Medicine at the University of British Columbia, and holder of the Johal Chair in Childhood Cancer Research. An internationally recognized molecular pathologist and cancer researcher, he has made pioneering contributions to understanding the genetic and molecular mechanisms underlying aggressive cancers, particularly pediatric malignancies.

His discoveries have advanced molecular diagnostics and contributed to the development of targeted therapeutic strategies. Dr. Sorensen's research bridges fundamental cancer biology with translational medicine, and his contributions have been recently recognized with the 2025 Dr. Chew Wei Memorial Prize in Cancer Research from the UBC Faculty of Medicine.

Dr. S. Larry Goldenberg

Dr. Goldenberg is an internationally recognized urologic surgeon, clinician-scientist and leader in prostate cancer research and men's health. A Professor at the University of British Columbia and founding head of its Department of Urologic Sciences, he has played a central role in establishing British Columbia as a leading centre for prostate cancer research, clinical innovation and patient care.

His contributions include advancing treatment strategies, molecular diagnostics, imaging technologies and multidisciplinary research programs. With more than four decades of leadership in urologic oncology, Dr. Goldenberg was recently honoured with the 2026 UBC Medicine Bill and Marilyn Webber Lifetime Achievement Award in recognition of his distinguished career in medical research, teaching and service.

Michael Liou

Mr. Liou is an experienced venture capital investor, strategic advisor and technology executive with extensive expertise in artificial intelligence, early-stage investing, corporate strategy and strategic partnerships. He has invested in more than 160 early-stage companies, including Robinhood, SpaceX, Zapier and numerous emerging AI and technology ventures.

He previously served as President of Chooch, an AI technology company, where he focused on corporate strategy, go-to-market initiatives and enterprise partnerships. His earlier career included senior roles at Citi Private Bank and 18 years at Goldman Sachs, where he served as Managing Director overseeing multiple business units. Mr. Liou also has advisory experience with major technology organizations, including Intel and Microsoft. His expertise in emerging technologies, investment strategy and business development will provide valuable perspective as Artemis pursues its strategic growth and commercialization opportunities.

Jordan Zwick

Mr. Zwick is Co-Founder and Chief Business Officer of Mirador Therapeutics and a Venture Partner at ARCH Venture Partners. He is an experienced biopharmaceutical executive with extensive expertise in corporate strategy, business development, capital markets and value creation across public and private life sciences companies.

Throughout his career, Mr. Zwick has advised on and led numerous strategic transactions, including serving as a strategic advisor to Prometheus Biosciences prior to its acquisition

by Merck in 2023 and to CrossBridge Bio through its acquisition by Eli Lilly in 2026. Mr. Zwick previously served as Senior Vice President of Corporate Business Development and Investor Relations at Amarin Corporation and as Senior Vice President and Chief Strategy Officer at Inflarx N.V., with earlier positions at Medtronic, Salix Pharmaceuticals and Bausch Health. His experience in biotechnology financing, strategic partnerships and corporate development will support Artemis as it advances its therapeutic programs and evaluates opportunities for growth.

Integrating AI, Biology and Clinical Insight to Advance Drug Discovery

The formation of the Advisory Board comes as Artemis advances its proprietary *Artemis.AI*™ platform, which integrates artificial intelligence, machine learning, computational chemistry and structural biology to accelerate the identification and development of novel therapeutics.

Built on more than 20 years of research led by Artemis co-founder and President Dr. Artem Cherkasov, the underlying technology has contributed to the discovery of eight drug candidates licensed to pharmaceutical companies. Its large-scale screening capabilities were also demonstrated during the COVID-19 pandemic, when 40 billion chemical compounds were screened in just 19 days.

The combination of computational innovation and deep expertise in cancer biology provides a foundation for Artemis to identify promising therapeutic candidates and pursue rigorous biological validation. The Advisory Board adds further scientific, clinical and business perspectives to support the advancement of the Company's drug programs.

Advancing an Asset-Driven Strategy for Therapeutic Value Creation

Unlike traditional AI drug discovery service providers, Artemis is pursuing an asset-driven strategy focused on identifying, validating and advancing its own therapeutic candidates. This approach is designed to capture greater value from the Company's discoveries while creating opportunities for strategic partnerships and licensing.

The Advisory Board complements the expertise of Artemis' founding leadership team by bringing additional perspectives in computational science, oncology, clinical medicine, investment and biotechnology commercialization.

By combining advanced computational technologies with rigorous biological validation and the expertise of its Advisory Board, Artemis aims to advance promising therapeutic candidates while retaining greater ownership of the value created through its discoveries. The Company believes this approach also positions it to pursue strategic partnerships and licensing opportunities as its therapeutic pipeline progresses.

About Artemis Therapeutics

Artemis Therapeutics Inc. is a privately held drug discovery and development company developing advanced artificial intelligence technologies to accelerate the identification and development of novel therapeutics.

Utilizing its *Artemis.AI*™ platform, the Company integrates computational chemistry, structural biology and machine learning to enable the exploration of complex chemical and biological systems at scale.

Artemis brings together leading expertise in artificial intelligence, computational molecular science and drug discovery with the objective of making the therapeutic discovery and development process faster, more precise and more efficient.

Contact

Vanessa Ooms, *Marketing & Communications Director*
ARTEMIS THERAPEUTICS INC.
vooms@artemistherapeutics.ai